These shares have doubled over the past month . We expect a further rise in price, testing the $0.50 cent level shortly . Emerald Research Report
RTSL’s business model is being executed by a superior management team with over 150 years of combined experience in capital markets and public company operations . A new world of therapeutic CBD products is at hand and RTSL is at the forefront leading the way.
The company expects a NASDAQ up – listing within 12 months. The company has a $2.5 million run rate and has launched its FDA listed pressurized metered dose inhaler (pMDI ) , soon rolling out a complete consumer focused product line. These products have been successfully tested by NFL, MLB and collegiate athletes
Tightly controlled with 85% of all shares are owned by management these shares are ready to rumble . We urge all serious investors to place these shares on their BUY LIST
Rapid Therapeutic Completes Delivery of Additional 6,000 Units of its Proprietary Metered Dose Inhalers
DALLAS, July 14, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and THC, announced today that it has delivered an additional 6,000 units (8,000 total) under its previously announced 100,000 unit order that was recently expanded to 250,000 units.
The Company has leased a state-of-the-art lab tested to ISO 6 standards and maintains general facility/process controls in its environmentally filtered operations, as part of compliance with FDA Good Manufacturing Practices (GMP) related to ISO 13485. This lab will allow the company to pursue RTSL’s stated goal of FDA registration of all RTSL products.
Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “This 6,000-unit lot was the last production run before we relocated to our new ISO 13485 lab. Our new lab allows us to manufacture a higher-quality product more quickly, and with less waste than we could previously.”
Mr. Schmidt continued, “With an estimated gross margin of approximately $20 per unit, this order for 250,000 units, by itself, could represent up to $5,000,000 in gross profit for the Company. Our RxoidTM CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States.”
Research report prepared by Brian R. Connell, Chartered Financial Analyst (CFA) offers in-depth analysis of Company’s business and likely future growth
DALLAS, June 22, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing CBD aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that Emerald Equity Research, LLC has initiated research coverage on the Company.To view and download the report (at no cost) CLICK HERE.
To view and download the report (at no cost) CLICK HERE.
While FDA Advances Work Related to Cannabidiol Products CBD Usage Rates Are On The Rise
Palm Beach, FL – June 30, 2020 – Just a few years ago, not many people knew what CBD is… or does. Things have really changed so much so that now, it’s harder to find someone who does not know what it is! A recent report said that 86% of Americans know about CBD and 1 in 5 have used it, according to a new analysis by New Frontier Data. It said: “Findings in the report suggest that cannabidiol (CBD) has never been more popular in the United States… Relatively unknown only years ago, CBD has since exploded into a fast-growing market that generates as much as $1 billion in domestic sales. The now widely recognized cannabis compound is used to promote health and wellness in users. The new nationally representative survey indicates that usage rates of CBD are rising.” “Our research shows that 1 in 5 Americans have used CBD, which demonstrates a major jump in consumer interest in the sector,” said New Frontier Data Founder & CEO Giadha Aguirre de Carcer. “While this phenomena is taking root across many other regions such as Europe and Latin America, the United States continues to represent the largest CBD market; understanding its CBD consumers is therefore a priority for enterprises within both the legal cannabis industry and a multitude of mature sectors such as Food & Beverage or Health & Beauty.” Mentioned in today’s commentary include: Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Rapid Therapeutic Science Laboratories, Inc. (OTCPK: RTSL), Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), CV Sciences, Inc. (OTCQB: CVSI).
And there is hope in the industry that once FDA approvals begin being granted, the market will have yet another infusion to even further boost the markets revenues. The FDA recently said: “The marketplace for CBD-containing products is quickly evolving and it is critical that we work together with stakeholders and industry to develop high-quality data to close the knowledge gaps about the science, safety and quality of many of these products, as well as further evaluate any potential benefits… “
Rapid Therapeutic Science Laboratories, Inc. (OTCPK: RTSL) Breaking News: Rapid Therapeutic Enters Contract for Certified Lab for Manufacturing Consistent with FDA Rules – Rapid Therapeutic Science Laboratories (the “Company” or “RTSL”), a SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has executed a contract leasing a new state-of-the-art laboratory. The laboratory is being certified for manufacturing under Food and Drug Administration (FDA) rules.
Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “We are extremely pleased to announce the Company has leased a state-of-the-art lab tested to ISO 6 standards. This lab will allow us to immediately pursue RTSL’s stated goal of FDA registration of all RTSL products. RTSL will immediately begin manufacturing according to ISO 13485 standards for medical devices.” https://www.iso.org/iso-13485-medical-devices.html. https://www.iso.org/standard/59752.html. The FDA adopted this standard in 2018. https://www.iso.org/news/ref2318.html.
Sean Berrier, Sr. VP and Co-founder commented: “RTSL will not maintain the lab as a certified “clean room,” instead the Company maintains general facility/process controls in its environmentally filtered operations, as part of compliance with FDA Good Manufacturing Practices (GMP) related to ISO 13485. Nevertheless, RTSL will periodically perform random testing to assess initial set-up, filter functional efficacy, personnel gowning consistency, and general process stability. Under ISO 13485 the lab rooms will function as “control rooms.” The goal is to organize layout, and minimize overhead particulate matter, thereby optimizing process flow and reducing product fallout. This allows for RTSL to manufacture a class II medical device under GMP. We believe we are one of only a handful of companies manufacturing CBD consumer products with this level of sophistication. This lab gives our clients a high level of assurance that our products are safe and clean with no adulterations.” Read the full Press Release and more for RTSL at: https://www.financialnewsmedia.com/news-rtsl
In other active company news in the markets this week:
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) recently announced that that at its Annual and Special Meeting of Shareholders held earlier today (the “Meeting”) there were 652 shareholders voting in person or by proxy holding in total 195,124,634 common shares of the Company, representing 55.94% of the total number of common shares of the Company outstanding.
Each of the directors listed as a nominee in the Company’s proxy statement dated April 28, 2020 (the “Proxy Statement”) was elected as a director of the Company, with each director receiving in excess of 97.10% of the votes cast in favor of his or her election.
The Company also announced today that the shareholders have approved a special resolution authorizing the Company to make an application for the continuance of the Company from the laws of the Province of Ontario to the laws of the Province of British Columbia, as further described in the Proxy Statement (the “Continuance”). The Company believes the greater flexibility afforded by the British Columbia corporate statute by virtue of the absence of a Canadian residency requirement for members of the board of directors of the Company (the “Board”) will allow the Company to consider Board candidates from a larger pool of candidates to ensure the Board maintains the right composition, skills, expertise and diversity to drive long-term value. The completion of the Continuance remains subject to the satisfaction of the conditions described in the Proxy Statement.
Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) and Acreage Holdings, Inc. (“Acreage”) recently announced they have entered into an agreement (the “New Agreement”) to amend the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, between Canopy Growth and Acreage (the “Arrangement Agreement”).
Pursuant to the Arrangement Agreement, Canopy Growth agreed to acquire all of the issued and outstanding securities of Acreage pursuant to a plan of arrangement under the Business Corporations Act (British Columbia) (the “Plan of Arrangement”), contingent upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana (the “Triggering Event”) and subject to the satisfaction or waiver of certain conditions to closing as set out in the Arrangement Agreement.
CV Sciences, Inc. (OTCQB: CVSI) recently announced the publication of two research studies demonstrating the safety and health benefits of PlusCBD™ products. Both studies were published in the Journal of Dietary Supplements. The first study adds to the growing body of literature that supports the safe use of hemp derived CBD as a dietary supplement. The data confirm a low rate of adverse effects in millions of consumers taking PlusCBD™ products over a two-year period. A noteworthy finding was the absence of any reports of liver toxicity, which has been described in studies using high doses of CBD as a prescription drug.
Lead author Stephen Schmitz, MD, MPH and co-founder of Supplement Safety Solutions, stated, “This is the first longitudinal study of a CBD dietary supplement being used in real-world conditions. This study represents two years of data and daily product use from millions of consumers and demonstrates that CV Sciences’ products are safe and well tolerated.”
Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) recently announced its majority-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried flower products to Saskatchewan following approval from the Saskatchewan Liquor and Gaming Authority (the “SLGA”), the provincial regulator responsible for permitting and monitoring the operation of local cannabis wholesalers and retailers in the Province. Pure Sunfarms expects its products to be available to Saskatchewanconsumers beginning next week.
Saskatchewan ranks as the fifth largest Canadian province by cannabis sales, comprising approximately 6% of the country’s total sales1 and has the second highest per capita spend on cannabis of the five largest provinces1 (behind Alberta). Saskatchewan currently has 44 licensed retailers and with the SLGA’s announcement to move towards an open market cannabis model by September of this year, there will be no cap on the number of dispensaries permitted in municipalities provincewide which is expected to give more consumers access to product.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty six hundred dollars for news coverage of current press release issued by Rapid Therapeutic Science Laboratories, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statement
We encourage all customers to do their own research regarding cannabinoids, the use of MDIs and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.